Tax Inversion

Five things for Pharma Marketers to know: Monday, September 29

Five things for Pharma Marketers to know: Monday, September 29

By

Inversion rules have Medtronic asking for a Covidien do-over, Roche's Perjeta has "unprecedented success," while AstraZeneca's Iressa does not.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Walgreen keeps US tax status

The Illinois company says it is keeping the US as its home base, which means no inversion benefit.

Shire, AbbVie join forces for $55B

Shire, AbbVie join forces for $55B

By

The deal includes a $1.6-billion fee if AbbVie tries to walk away.

Shire asks AbbVie for more money

Shire asks AbbVie for more money

By

Shire and AbbVie's courtship has entered round five. A deal would offer AbbVie tax relief, and possibly make it an acquisition target.

Abbott pairs generics with tax benefit

Abbott and Mylan are setting up a generics business. The all-stock deal will give some branded generics a new home and offer Abbott a tax benefit that will increase over time.

Salix heads to Ireland

Salix heads to Ireland

By

Salix Pharmaceuticals joins the tax-inversion migration by purchasing Cosmo Technologies.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.